clinical trial · NCT06187402
A Study of LM-24C5 For Advanced Solid Tumors
Advanced Solid TumorLM-24C5
brief summary
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
started
Dec 20, 2023
primary completion
Jun 30, 2026
completion
Dec 30, 2026
last updated
Sep 9, 2025
official title
A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol